Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06700841 IR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-06700841: IR, MR1, MR2, MR1_fed | EXPERIMENTAL | Participants receive single doses of immediate release (IR) followed by modified release (MR) MR1 and MR2, all in fasted condition followed by MR1 in fed condition in Periods 1-4 |
| PF-06700841: MR1, MR2, IR, MR1_fed | EXPERIMENTAL | Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR1 in fed condition in Periods 1-4 |
| PF-06700841: MR2, IR, MR1, MR1_fed | EXPERIMENTAL | Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR1 in fed condition in Periods 1-4 |
| PF-06700841: IR, MR1, MR2, MR2_fed | EXPERIMENTAL | Participants receive single doses of IR followed by MR1 and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4 |
| PF-06700841: MR1, MR2, IR, MR2_fed | EXPERIMENTAL | Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR2 in fed condition in Periods 1-4 |
| PF-06700841: MR2, IR, MR1, MR2_fed | EXPERIMENTAL | Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4 |
| PF-06700841 MR3 (Dose A) or matching placebo | EXPERIMENTAL | Participants receive dosing regimen 1 of MR3 (Dose A) or matching placebo for 7 days under fasted condition |
| PF-06700841 MR3 (Dose B) or matching placebo | EXPERIMENTAL | Participants receive dosing regimen 1 of MR3 (Dose B) or matching placebo for 7 days under fasted condition |
| PF-06700841 MR3 (Dose C) or matching placebo | EXPERIMENTAL | Participants receive dosing regimen 1 of MR3 (Dose C) or matching placebo for 7 days under fasted condition |
| Name | Type | Description |
|---|---|---|
| PF-06700841 IR | DRUG | Immediate release formulation |
| PF-06700841 MR1 | DRUG | Modified release formulation 1 |
| PF-06700841 MR2 | DRUG | Modified release formulation 2 |
| PF-06700841 MR3 | DRUG | Modified release formulation 3 |
| Placebo | OTHER | Matching placebo |
Inclusion Criteria: * Healthy male and female participants between 18 -55 years of age. * BMI of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb). * Participants who are willing and able to comply with all scheduled visits, treatment * plan, laboratory tests, lifestyle considerations, a...
PF-06700841 IR is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE). The IR designation refers to an immediate-release formulation. It has been studied in a Phase 1 clinical trial in healthy participants, and its therapeutic indications have not been disclosed.
PF-06700841 IR is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 clinical trial of this asset.
PF-06700841 IR is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The drug is investigational and has not been approved by the FDA for any indication.
PF-06700841 IR has been evaluated in one completed Phase 1 trial, NCT04580797, titled "Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations." The trial enrolled 36 healthy participants in the United States.
The Phase 1 trial NCT04580797 was a randomized, double-blind, controlled study of PF-06700841 IR in 36 healthy volunteers aged 18 years and older. It assessed pharmacokinetics and safety after single and multiple oral doses of modified-release formulations. The trial has been completed.